DRI Capital Completes C$600M in Deals in 2012

DRI Capital, a Canadian private equity firm specializing in monetizing royalties it purchases from pharmaceutical and biotechnology companies and others, completed over C$600 million in deals in 2012. Among the firm’s disclosed transactions was the September 2012 acquisition of BENLYSTA royalty rights from Weston, Mass.-based Biogen Idec Ltd. DRI Capital, which celebrates its 20th anniversary in 2013, raised its last partnership, Drug Royalty Fund II, totaling C$700 million, in 2010.

DRI Capital Closes Second Drug Royalty Fund

DRI Capital, a private equity firm which invests in drug royalty streams, has closed its second fund with $701 million in capital commitments. It originally targeted $500 million, with Atlantic-Pacific Capital serving as placement agent.

DRI Crosses Fundraising Target, Doesn’t Stop

DRI Capital, a private equity firm which invests in drug royalty streams, has raised $600 million for its second fund, a source familiar with the situation said. The firm originally targeted $500 million for Drug Royalty II LP, but has continued to accept new commitments. DRI Capital’s first fund was a 2006 vintage with $800 […]

PEHUB Community

Join the 12493 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget

Groups